

Dr Reddy's cancer drug hits the US market

25 November 2014 | News | By BioSpectrum Bureau

Dr Reddy's cancer drug hits the US market



Dr Reddy's Laboratories has launched Docetaxel injection USP 20 mg/mL and 80 mg/4 mL, a generic version of Taxotere (docetaxel injection) in the US market.

According to the company, Docetaxel injection USP 20 mg/mL and 80 mg/4 mL are available as a single dose, one vial formulation that does not require a prior dilution with a diluent and is ready to add to the intravenous infusion solution.

Taxotere (docetaxel) is a cancer medication that interferes with the growth and spread of cancer cells in the body.